Finances, outlook, and valuation #msg-65530093P/E is only 11x based on 2011 guidance #msg-654697002Q11 sales in emerging markets +23% to $10.4B rate #msg-61658082 ABT is undervalued, says Barron’s (Apr 2011) #msg-60102300 ABT hikes dividend for 39th consecutive year! #msg-32844386 New $5B buyback authorization #msg-34774636 ABT’s M&A track record is second to none (Jan 2009)
Durable Growth segment #msg-655291402Q11 sales of top products and franchises #msg-654697002Q11 sales in emerging markets +23% to $10.4B rate #msg-61699995 Drug sales in emerging markets: $400B in 2020 (IMS) #msg-50473238India’s fake drugs are a real problem #msg-61960541 Branded generics in emerging markets—connecting the dots #msg-62037218 More on branded generics (Forbes)
Proprietary Pharma segment #msg-655291402Q11 sales of top products and franchises #msg-61383188 Pipeline overview (Apr 2011)
#msg-64677120Humira will be world’s biggest drug in 2012 #msg-61383188Investors overplay JAK threat to Humira #msg-62953768 Humira hit primary endpoint in ulcerative colitis #msg-61989536 Antibodies against Humira are no big deal #msg-39417561 Size and segments of US market for RA #msg-64449921 ABT licenses anti-CD4 mAb from Biotest AG
#msg-63350663 Panel supports continued use of TriCor/TriLipix w statins #msg-62207709 Capsule summary of TriCor ACCORD study #msg-62591674 Bearish musings on TriCor/TriLipix (Forbes) #msg-51992958 Does TriCor prevent diabetic retinopathy? #msg-34203456 FDA approves TriLipix (Dec 2008) #msg-33503193 TriLipix + statin 1-year combo data
#msg-63617748 NIH terminates Niaspan AIM-HIGH study #msg-28510348 Heart disease: Not about cholesterol? #msg-63656000 Once is happenstance, twice is coincidence, three times…
#msg-64332248 Bardoxolone advances to phase-3 #msg-56946507 Phase-2b Bardoxolone data #msg-54747777 ABT licenses Reata’s Bardoxolone for CKD #msg-66027502 Daclizumab succeeds in phase-2b; safety questions remain #msg-50509176 Phase-3 Daclizumab trial in RRMS begins #msg-57504180 Phase-2 Elotuzumab Data in MM #msg-51343858 ABT licenses NBIX’s Elagolix for endometriosis #msg-62599720 FDA approves ‘low volume’ Androgel #msg-61757048 Multi-pronged program in HCV #msg-52406597 Nuke-sparing HIV program (Kaletra+Isentress) #msg-58794717 ABT withdraws BLA/MAA for Briakinumab
Innovative Devices segment #msg-655291402Q11 sales of top products and franchises #msg-65470041 60% of Xience sales are ex-US #msg-64256077 JNJ withdraws from DES business #msg-54841998 Xience continues to best Taxus in SPIRIT IV #msg-41731638 Xience blows away Taxus at three years in SPIRIT III #msg-54842212 Xience crushes Taxus Liberté at 2 years #msg-38097301 Xience shines in hard-to-treat subgroups #msg-38985789 EU approves Xience Prime (Jun 2009)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.